Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-624 in Healthy Volunteers and Major Depressive Disorder
NCT06570369Phase 1Completed
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
- Start
- Aug 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing SP-624 with Placebo (2 arms). Primary endpoint: Brain Network Analytics Profile at 2 weeks. Started Aug 2024; status: completed.
02
Drugs
forvisirvat
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06570369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06570369.